Coramitug is well tolerated and leads to a statistically significant reduction in N-terminal pro-brain type natriuretic peptide (NT-proBNP)—a marker of disease progression in transthyretin-mediated ...

The mean cost savings associated with tafamidis treatment due to a reduction in hospitalization because of heart failure and shortening of length of stay in the hospital was $12,940 per patient.

Important gains were observed in key areas, including basic theory, transfusion compatibility testing, and clinical transfusion application. A structured 6-month fellowship program in transfusion ...

Diagnostic performance for key IPF hallmarks, including honeycombing, reticulation, and basal predominance, was consistently high. Ultrashort echo time magnetic resonance imaging (UTE-MRI) accurately ...

Between 21.4% and 57.8% of patients from a real-world ATTR-CM cohort would have been eligible to take part in clinical trials testing disease-modifying therapies. Inclusion and exclusion criteria used ...

The ratio of posterior wall thickness to the minimum voltage of QRS complexes in limb leads and several parameters derived from electrocardiography could independently predict ATTR-CM. The ratio of ...

Diagnosis of neurofibromatosis type 1 (NF1) requires a combination of clinical assessment, genetic testing, and imaging studies. 1 NF1 is a rare genetic disorder characterized by the development of ...

The devices are available for patients aged 17 years and older at no extra cost and can be used after receiving training from a healthcare professional. Two new medical devices that will facilitate ...

Bezuclastinib is designed to selectively and potently target the KIT D816V mutation and other mutations within KIT exon 17. Bezuclastinib, a selective tyrosine kinase inhibitor, has received ...

NMOSD is a rare autoimmune disorder characterized by inflammation and demyelination of nerves in the central nervous system (CNS), particularly the optic nerves and spinal cord. It typically manifests ...